Eventually, as scientific data established a clear correlation between smoking and lung cancer, the regulatory landscape shifted towards discouraging smoking.
It wasn't until Tarceva extended the lives of patients with non-small cell lung cancer that it became clear that OSI and Genentech actually did have a potential blockbuster on their hands.